Methyltetrahydrofolate vs Folic Acid Supplementation in Idiopathic Recurrent Miscarriage with Respect to Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphisms: A Randomized Controlled Trial
Open Access
- 2 December 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (12) , e0143569
Abstract
To determine whether 5-methylenetetrahydrofolate (MTHF) is more effective than folic acid supplementation in treatment of recurrent abortion in different MTHFR gene C677T and A1298C polymorphisms. A randomized, double blind, placebo-controlled trial conducted April 2011-September 2014 in recurrent abortion clinics in Tehran, Iran. The participants were women with three or more idiopathic recurrent abortion, aged 20 to 45 years. Two hundred and twenty eligible women who consented to participate were randomly assigned to receive either folic acid or 5-MTHF according to the stratified blocked randomization by age and the number of previous abortions. Participants took daily 1 mg 5-methylentetrahydrofolate or 1 mg folic acid from at least 8 weeks before conception to the 20th week of the pregnancy. The primary outcome was ongoing pregnancy rate at 20th week of pregnancy, and the secondary outcomes were serum folate and homocysteine at the baseline, after 8 weeks, and at the gestational age of 4, 8, 12, and 20 weeks, MTHFR gene C677T and A1298C polymorphisms. There was no significant difference in abortion rate between two groups. Serum folate increased significantly in both groups over time; these changes were significantly higher in the group receiving 5-MTHF than the group receiving folic acid (value = 2.39, p<00.1) and the result was the same by considering the time (value = 1.24, p<0.01). Plasma tHcys decreased significantly in both groups over time; however these changes were not significantly different between the groups (value = 0.01, p = 0.47). The results do not support any beneficial effect of 5-MTHF vs. folate supplementation in women with recurrent abortion with any MTHFR C677T and/or A1298C polymorphism. ClinicalTrials.gov NCT01976676Keywords
This publication has 37 references indexed in Scilit:
- Association of maternal and fetal MTHFR A1298C polymorphism with the risk of pregnancy loss: a study of an Indian population and a meta-analysisFertility and Sterility, 2013
- Is 5-methyltetrahydrofolate an alternative to folic acid for the prevention of neural tube defects?Journal of Perinatal Medicine, 2013
- Plasma homocysteine and vitamin B12 serum levels, red blood cell folate concentrations, C677T methylenetetrahydrofolate reductase gene mutation and risk of recurrent miscarriage: a case-control study in SpainClinical Chemistry and Laboratory Medicine (CCLM), 2013
- A pilot study on environmental and behavioral factors related to missed abortionEnvironmental Health and Preventive Medicine, 2011
- [6S]‐5‐methyltetrahydrofolate increases plasma folate more effectively than folic acid in women with the homozygous or wild‐type 677C→T polymorphism of methylenetetrahydrofolate reductaseBritish Journal of Pharmacology, 2009
- Methylenetetrahydrofolate reductase C677T polymorphism and the risk of unexplained recurrent pregnancy loss: A meta-analysisFertility and Sterility, 2006
- Folic acid supplements in pregnancy and birth outcome: re‐analysis of a large randomised controlled trial and update of Cochrane reviewPaediatric and Perinatal Epidemiology, 2005
- Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control studyBMJ, 2004
- Preconception folate and vitamin B6 status and clinical spontaneous abortion in Chinese womenObstetrics & Gynecology, 2002
- Vitamin supplementation and pregnancy outcome in women with recurrent early pregnancy loss and hyperhomocysteinemiaFertility and Sterility, 2001